Stephen A. Cullinan

2.3k total citations · 1 hit paper
25 papers, 1.8k citations indexed

About

Stephen A. Cullinan is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stephen A. Cullinan has authored 25 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 7 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stephen A. Cullinan's work include Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (6 papers) and Breast Cancer Treatment Studies (6 papers). Stephen A. Cullinan is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (6 papers) and Breast Cancer Treatment Studies (6 papers). Stephen A. Cullinan collaborates with scholars based in United States and Canada. Stephen A. Cullinan's co-authors include James E. Krook, Loren K. Tschetter, Harry S. Wieand, J A Mailliard, Lloyd K. Everson, C G Moertel, Michael A. Poon, John A. Laurie, M. J. OʼConnell and John Foley and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Cancer.

In The Last Decade

Stephen A. Cullinan

24 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

1989 725 citations Michael A. Poon, M. J. OʼConnell et al. Journal of Clinical Oncology profile →

Peers

Stephen A. Cullinan

ONCOL

PRM

SURGE

PFM

D. Depisch Austria

Massimo Lopez Italy

Kurt Brunner Switzerland

Robert M. OʼBryan United States

M J O'Connell United States

Stephen Shibata United States

J. L. Misset France

James D. Ahlgren United States

Salvatore Artale Italy

Kenjiro Kotake Japan

D. Depisch Austria

Stephen A. Cullinan

2.0k ×1.5

ONCOL

895 ×1.3

PRM

939 ×2.4

SURGE

386 ×1.3

240 ×1.1

PFM

Citations per year, relative to Stephen A. Cullinan Stephen A. Cullinan (= 1×) peers D. Depisch

Countries citing papers authored by Stephen A. Cullinan

Since Specialization

Citations

This map shows the geographic impact of Stephen A. Cullinan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen A. Cullinan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen A. Cullinan more than expected).

Fields of papers citing papers by Stephen A. Cullinan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen A. Cullinan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen A. Cullinan. The network helps show where Stephen A. Cullinan may publish in the future.

Co-authorship network of co-authors of Stephen A. Cullinan

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen A. Cullinan. A scholar is included among the top collaborators of Stephen A. Cullinan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen A. Cullinan. Stephen A. Cullinan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lichtman, Stuart M., Donna Hollis, Antonius A. Miller, et al.. (2006). Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762). Journal of Clinical Oncology. 24(12). 1846–1851. 66 indexed citations

Cullinan, Stephen A., C G Moertel, Harry S. Wieand, et al.. (1994). Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group.. Journal of Clinical Oncology. 12(2). 412–416. 114 indexed citations

Ingle, James N., Harry J. Long, Donald I. Twito, et al.. (1991). Combination hormonal therapy with tamoxifen plus fluoxymesteroneversus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer. 67(4). 886–891. 91 indexed citations

Cullinan, Stephen A., Charles G. Moertel, Harry S. Wieand, et al.. (1990). A phase III trial on the therapy of advanced pancreatic carcinoma evaluations of the mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer. 65(10). 2207–2212. 171 indexed citations

Everson, Lloyd K., James R. Jett, Judith R. OʼFallon, et al.. (1989). Alternating Chemotherapy With or Without VP-16 in Extensive-Stage Small-Cell Lung Cancer. American Journal of Clinical Oncology. 12(4). 339–344. 8 indexed citations

Ingle, James N., Lloyd K. Everson, Harry S. Wieand, et al.. (1989). Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. Cancer. 63(7). 1257–1264. 24 indexed citations

Buckner, Jan C., Lloyd K. Everson, Judith R. OʼFallon, et al.. (1989). Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer. Breast Cancer Research and Treatment. 13(2). 135–142. 19 indexed citations

Marschke, Robert F., James N. Ingle, Daniel J. Schaid, et al.. (1989). Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. Cancer. 63(10). 1931–1937. 8 indexed citations

Poon, Michael A., M. J. OʼConnell, C G Moertel, et al.. (1989). Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.. Journal of Clinical Oncology. 7(10). 1407–1418. 725 indexed citations breakdown →

10.

Ingle, James N., Lloyd K. Everson, Lester E. Wold, et al.. (1989). Randomized Trial of Observation Versus Adjuvant Therapy With Cyclophosphamide, Fluorouracil, Prednisone With or Without Tamoxifen Following Mastectomy in Postmenopausal Women With Node-Positive Breast Cancer. Journal of Clinical Oncology. 7(1). 145–145.

11.

Ingle, James N., Lloyd K. Everson, Harry S. Wieand, et al.. (1988). Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer.. Journal of Clinical Oncology. 6(9). 1388–1396. 35 indexed citations

12.

Ingle, James N., Donald I. Twito, Daniel J. Schaid, et al.. (1988). Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer.. Journal of Clinical Oncology. 6(5). 825–831. 23 indexed citations

13.

Marschke, Robert F., Larry K. Kvols, Stephen A. Cullinan, et al.. (1988). Phase II study of bisantrene administered by continuous 72‐hour infusion for advanced pancreatic adenocarcinoma. Medical and Pediatric Oncology. 16(4). 269–270. 2 indexed citations

14.

Edmonson, J H, Patrick S. Johnson, H. Samuel Wieand, et al.. (1988). Phase II Studies of Bleomycin, Cyclophosphamide, Doxorubicin and Cisplatin, and Bleomycin and Cisplatin in Advanced Cervical Carcinoma. American Journal of Clinical Oncology. 11(2). 149–151. 11 indexed citations

15.

Mj, O'Connell, et al.. (1987). Clinical studies of biochemical modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer by the North Central Cancer Treatment Group and Mayo Clinic.. PubMed. 185–8. 2 indexed citations

16.

Morton, Roscoe F., Edward T. Creagan, Stephen A. Cullinan, et al.. (1987). Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma.. Journal of Clinical Oncology. 5(7). 1078–1082. 22 indexed citations

17.

Buroker, T, C G Moertel, Thomas R. Fleming, et al.. (1985). A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.. Journal of Clinical Oncology. 3(12). 1624–1631. 90 indexed citations

18.

Krook, James E., James R. Jett, Thomas R. Fleming, et al.. (1985). A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 3(6). 842–848. 13 indexed citations

19.

Ingle, James N., Stephanie Green, S. Fred Brunk, et al.. (1985). Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure. American Journal of Clinical Oncology. 8(4). 275–282. 13 indexed citations

20.

Windschitl, Harold E., Martin Scott, Allan J. Schutt, et al.. (1983). Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.. PubMed. 67(11). 1001–8. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact